Innate Pharma Presents MATISSE Phase 2 Study Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy IPHA?
Source: Yahoo Finance
- Clinical Trial Progress: Innate Pharma will present interim results from the MATISSE Phase 2 study at the AACR Annual Meeting 2026, evaluating the combination of IPH5201 with durvalumab and chemotherapy in resectable non-small cell lung cancer (NSCLC), which is expected to garner significant attention.
- Efficacy Data Highlights: The pre-planned analysis of 40 patients showed a pathological complete response (pCR) rate of 35.7% and 50% for the combination of IPH5201 with durvalumab and chemotherapy, significantly outperforming the benchmark set by durvalumab alone, potentially offering new treatment options for NSCLC patients.
- Study Design and Objectives: The MATISSE study aims to assess the anti-tumor immune response of dual inhibition of CD39 and PD-L1 pathways combined with chemotherapy, particularly in patients with PD-L1 expression ≥50%, highlighting the necessity for novel treatment strategies in early-stage lung cancer.
- Future Research Directions: Innate Pharma will continue to recruit patients with PD-L1 expression ≥1% to further validate the efficacy of the interim results, indicating the company's ongoing commitment and innovative potential in lung cancer treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IPHA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IPHA
Wall Street analysts forecast IPHA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.620
Low
5.00
Averages
6.50
High
8.00
Current: 1.620
Low
5.00
Averages
6.50
High
8.00
About IPHA
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Innate Pharma Presents MATISSE Phase 2 Study Results
- Clinical Trial Progress: Innate Pharma will present interim results from the MATISSE Phase 2 study at the AACR Annual Meeting 2026, evaluating the combination of IPH5201 with durvalumab and chemotherapy in resectable non-small cell lung cancer (NSCLC), which is expected to garner significant attention.
- Efficacy Data Highlights: The pre-planned analysis of 40 patients showed a pathological complete response (pCR) rate of 35.7% and 50% for the combination of IPH5201 with durvalumab and chemotherapy, significantly outperforming the benchmark set by durvalumab alone, potentially offering new treatment options for NSCLC patients.
- Study Design and Objectives: The MATISSE study aims to assess the anti-tumor immune response of dual inhibition of CD39 and PD-L1 pathways combined with chemotherapy, particularly in patients with PD-L1 expression ≥50%, highlighting the necessity for novel treatment strategies in early-stage lung cancer.
- Future Research Directions: Innate Pharma will continue to recruit patients with PD-L1 expression ≥1% to further validate the efficacy of the interim results, indicating the company's ongoing commitment and innovative potential in lung cancer treatment.
See More
Innate Pharma to Hold 2026 Annual General Meeting
- AGM Details: Innate Pharma will hold its Annual General Meeting on May 21, 2026, at 10:30 a.m. CEST at its Marseille headquarters, with the notice published on April 13, 2026, ensuring shareholders are informed about the agenda and proposed resolutions.
- Attendance Requirements: Only shareholders who register their shares at least five trading days prior to the AGM, specifically by May 14, 2026, will be eligible to attend, safeguarding shareholder rights and participation.
- Laboratory Tour Opportunity: A guided tour of the company's laboratories will take place on the same day at 9:15 a.m., allowing shareholders to register via a link, thereby enhancing interaction and transparency between the company and its shareholders.
- Information Access Channels: Shareholders can submit written questions via email and access AGM-related documents on the company's investor section, ensuring timely and transparent communication of information.
See More
Innate Pharma Discloses Share and Voting Rights Information
- Total Shares Disclosure: As of April 9, 2026, Innate Pharma reports a total of 93,860,680 shares outstanding, including 93,847,763 ordinary shares and 5,336 preferred shares, indicating stability in its capital structure which aids investors in assessing market position.
- Voting Rights Information: The company has a total of 94,484,443 theoretical voting rights and 94,465,868 exercisable voting rights, ensuring transparency in corporate governance and compliance with French financial market regulations, which may positively influence stock price stability.
- Compliance and Transparency: Innate Pharma's disclosures align with the French Commercial Code and AMF regulations, enhancing investor trust in corporate governance and compliance, potentially leading to a more stable stock performance.
- Company Background: Innate Pharma is a global clinical-stage biotechnology firm focused on developing immunotherapies for cancer, with a portfolio of differentiated potential first and/or best-in-class assets, showcasing its innovative capabilities and market potential in the biopharmaceutical sector.
See More
Innate Pharma to Present at AACR Oncology Event
- Key Presentation Opportunity: Innate Pharma's COO Yannis Morel will present at the AACR Oncology Industry Partnering Event on April 16, 2026, in San Diego, California, showcasing the company's innovative advancements in oncology drug development, which is expected to attract attention from investors and analysts.
- Clinical Pipeline Recognition: This presentation is seen as a recognition of Innate Pharma's clinical pipeline, particularly its Nectin-4 ADC (IPH4502), which could accelerate the development of its differentiated therapies to meet high unmet medical needs in the market.
- Industry Collaboration Platform: The AACR event brings together venture capitalists, investment bankers, and biopharmaceutical leaders, providing Innate Pharma with a valuable opportunity to connect with potential investors and partners, potentially facilitating future collaborations and funding support.
- Global Impact: As a global clinical-stage biotechnology company, Innate Pharma's presentation not only enhances its visibility in the field of oncology immunotherapy but may also pave the way for future innovative drug development, strengthening its competitive position in the market.
See More
Innate Pharma to Participate in Investor Meetings
- Investor Meeting Schedule: Innate Pharma will participate in the Kempen Life Sciences Conference on April 15-16, 2026, in Amsterdam, where its executive team will engage in one-on-one meetings with investors, aiming to enhance investor relations and increase company visibility.
- Innovative Drug Development: The company is advancing multiple immunotherapies for cancer, including IPH4502 and lacutamab, focusing on areas of high unmet medical need, which will help establish a competitive edge in the crowded biopharmaceutical market.
- Strategic Partnerships: Innate Pharma has formed collaborations with leading biopharmaceutical companies such as Sanofi and AstraZeneca, which not only bolster its R&D capabilities but also provide strong support for the market introduction of its innovative therapies.
- Global Business Presence: With its headquarters in Marseille, France, and an office in Rockville, MD, Innate Pharma's global footprint enables it to better address diverse market demands and drive its internationalization strategy.
See More
Innate Pharma Files 2025 Universal Registration Document
- Registration Document Filing: Innate Pharma filed its 2025 Universal Registration Document with the French market authority on April 1, 2026, which includes the annual financial and management reports, ensuring compliance and enhancing investor transparency.
- U.S. Report Submission: On the same day, Innate Pharma also submitted its Form 20-F annual report for 2025 to the SEC, further expanding its compliance in the U.S. market and boosting trust among international investors.
- Innovative Drug Development: The company focuses on developing immunotherapies for cancer patients, advancing multiple potential first-in-class assets, including IPH4502 and lacutamab, aimed at addressing high unmet medical needs and enhancing market competitiveness.
- Strategic Partnerships: Innate Pharma has established collaborations with leading biopharmaceutical companies like Sanofi and AstraZeneca, driving innovation in immuno-oncology and further solidifying its position in the biotechnology sector.
See More
Innate Pharma Presents MATISSE Phase 2 Study Results
- Clinical Trial Progress: Innate Pharma will present interim results from the MATISSE Phase 2 study at the AACR Annual Meeting 2026, evaluating the combination of IPH5201 with durvalumab and chemotherapy in resectable non-small cell lung cancer (NSCLC), which is expected to garner significant attention.
- Efficacy Data Highlights: The pre-planned analysis of 40 patients showed a pathological complete response (pCR) rate of 35.7% and 50% for the combination of IPH5201 with durvalumab and chemotherapy, significantly outperforming the benchmark set by durvalumab alone, potentially offering new treatment options for NSCLC patients.
- Study Design and Objectives: The MATISSE study aims to assess the anti-tumor immune response of dual inhibition of CD39 and PD-L1 pathways combined with chemotherapy, particularly in patients with PD-L1 expression ≥50%, highlighting the necessity for novel treatment strategies in early-stage lung cancer.
- Future Research Directions: Innate Pharma will continue to recruit patients with PD-L1 expression ≥1% to further validate the efficacy of the interim results, indicating the company's ongoing commitment and innovative potential in lung cancer treatment.
See More
Innate Pharma to Hold 2026 Annual General Meeting
- AGM Details: Innate Pharma will hold its Annual General Meeting on May 21, 2026, at 10:30 a.m. CEST at its Marseille headquarters, with the notice published on April 13, 2026, ensuring shareholders are informed about the agenda and proposed resolutions.
- Attendance Requirements: Only shareholders who register their shares at least five trading days prior to the AGM, specifically by May 14, 2026, will be eligible to attend, safeguarding shareholder rights and participation.
- Laboratory Tour Opportunity: A guided tour of the company's laboratories will take place on the same day at 9:15 a.m., allowing shareholders to register via a link, thereby enhancing interaction and transparency between the company and its shareholders.
- Information Access Channels: Shareholders can submit written questions via email and access AGM-related documents on the company's investor section, ensuring timely and transparent communication of information.
See More
Innate Pharma Discloses Share and Voting Rights Information
- Total Shares Disclosure: As of April 9, 2026, Innate Pharma reports a total of 93,860,680 shares outstanding, including 93,847,763 ordinary shares and 5,336 preferred shares, indicating stability in its capital structure which aids investors in assessing market position.
- Voting Rights Information: The company has a total of 94,484,443 theoretical voting rights and 94,465,868 exercisable voting rights, ensuring transparency in corporate governance and compliance with French financial market regulations, which may positively influence stock price stability.
- Compliance and Transparency: Innate Pharma's disclosures align with the French Commercial Code and AMF regulations, enhancing investor trust in corporate governance and compliance, potentially leading to a more stable stock performance.
- Company Background: Innate Pharma is a global clinical-stage biotechnology firm focused on developing immunotherapies for cancer, with a portfolio of differentiated potential first and/or best-in-class assets, showcasing its innovative capabilities and market potential in the biopharmaceutical sector.
See More
Innate Pharma to Present at AACR Oncology Event
- Key Presentation Opportunity: Innate Pharma's COO Yannis Morel will present at the AACR Oncology Industry Partnering Event on April 16, 2026, in San Diego, California, showcasing the company's innovative advancements in oncology drug development, which is expected to attract attention from investors and analysts.
- Clinical Pipeline Recognition: This presentation is seen as a recognition of Innate Pharma's clinical pipeline, particularly its Nectin-4 ADC (IPH4502), which could accelerate the development of its differentiated therapies to meet high unmet medical needs in the market.
- Industry Collaboration Platform: The AACR event brings together venture capitalists, investment bankers, and biopharmaceutical leaders, providing Innate Pharma with a valuable opportunity to connect with potential investors and partners, potentially facilitating future collaborations and funding support.
- Global Impact: As a global clinical-stage biotechnology company, Innate Pharma's presentation not only enhances its visibility in the field of oncology immunotherapy but may also pave the way for future innovative drug development, strengthening its competitive position in the market.
See More
Innate Pharma to Participate in Investor Meetings
- Investor Meeting Schedule: Innate Pharma will participate in the Kempen Life Sciences Conference on April 15-16, 2026, in Amsterdam, where its executive team will engage in one-on-one meetings with investors, aiming to enhance investor relations and increase company visibility.
- Innovative Drug Development: The company is advancing multiple immunotherapies for cancer, including IPH4502 and lacutamab, focusing on areas of high unmet medical need, which will help establish a competitive edge in the crowded biopharmaceutical market.
- Strategic Partnerships: Innate Pharma has formed collaborations with leading biopharmaceutical companies such as Sanofi and AstraZeneca, which not only bolster its R&D capabilities but also provide strong support for the market introduction of its innovative therapies.
- Global Business Presence: With its headquarters in Marseille, France, and an office in Rockville, MD, Innate Pharma's global footprint enables it to better address diverse market demands and drive its internationalization strategy.
See More
Innate Pharma Files 2025 Universal Registration Document
- Registration Document Filing: Innate Pharma filed its 2025 Universal Registration Document with the French market authority on April 1, 2026, which includes the annual financial and management reports, ensuring compliance and enhancing investor transparency.
- U.S. Report Submission: On the same day, Innate Pharma also submitted its Form 20-F annual report for 2025 to the SEC, further expanding its compliance in the U.S. market and boosting trust among international investors.
- Innovative Drug Development: The company focuses on developing immunotherapies for cancer patients, advancing multiple potential first-in-class assets, including IPH4502 and lacutamab, aimed at addressing high unmet medical needs and enhancing market competitiveness.
- Strategic Partnerships: Innate Pharma has established collaborations with leading biopharmaceutical companies like Sanofi and AstraZeneca, driving innovation in immuno-oncology and further solidifying its position in the biotechnology sector.
See More
